After Novavax (NVAX) announced that the company and Sanofi (SNY) have agreed to co-exclusive co-commercialization of Novavax’ COVID-19 vaccine and develop novel combination influenza plus COVID-19 vaccines, H.C. Wainwright analyst Vernon Bernardino did not make immediate changes to the firm’s models while the firm conducts further analysis of the full potential impact the Sanofi deal could have on future assumptions. However, the firm reiterates its Buy rating and $19 price target on Novavax shares.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVAX:
- NVAX Earnings: Novavax Soars After Stellar Growth in Revenue, Sanofi Deal Boost
- Options Volatility and Implied Earnings Moves Today, May 10, 2024
- Novavax Reports First Quarter 2024 Financial Results and Operational Highlights
- Novavax stockholder Shah Capital issues letter against board re-election
- NVAX Earnings this Week: How Will it Perform?